|
1) Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110: 673-87
|
|
|
|
2) Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004; 104: 1606-15
|
|
|
|
|
|
3) Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin αvβ3. Science. 2001; 294: 339-45
|
|
|
|
|
|
4) Xiao T, Takagi J, Coller BS, et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004; 432: 59-67
|
|
|
|
|
|
5) Takagi J, Petre BM, Walz T, et al. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002; 110: 599-611
|
|
|
|
|
|
6) Eto K, Murphy R, Kerrigan SW, et al. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci U S A. 2002; 99: 12819-24
|
|
|
|
|
|
7) Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004: 10: 982-6
|
|
|
|
|
|
8) Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, et al. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005; 115: 680-7
|
|
|
|
|
|
9) Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin βtails: a final common step in integrin activation. Science. 2003; 302: 103-6
|
|
|
|
|
|
10) Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007; 204: 3113-8
|
|
|
|
|
|
11) Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007; 204: 3103-11
|
|
|
|
|
|
12) Moser M, Legate KR, Zent R, et al. The tail of integrins, talin, and kindlins. Science. 2009; 324: 895-9
|
|
|
|
|
|
13) Larjava H, Plow EF, Wu C. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO reports. 2008; 9: 1203-8
|
|
|
|
|
|
14) Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008; 14: 325-30
|
|
|
|
|
|
15) Moser M, Bauer M, Schmid S, et al. Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion to endothelial cells. Nat Med. 2009; 15: 300-5
|
|
|
|
|
|
16) Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009; 15: 306-312
|
|
|
|
|
|
17) Malinin NL, Zhang L, Choi J, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med. 2009; 15: 313-7
|
|
|
|
|
|
18) Kuijpers TW, van de Vijver E, Weterman MA, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009; 113: 4740-6
|
|
|
|
|
|
19) Ma YQ, Qin J, Wu C, et al. Kindlin-2 (Mig-2): a co-activator of β3 integrins. J Cell Biol. 2008; 181: 439-46
|
|
|
|
|
|
20) Montanez E, Usser S, Schifferer M, et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008; 15: 1325-30
|
|
|
|
|
|
21) Harburger DS, Bouaouina M, Calderwood DA. Kindlin-1 and -2 directly bind the C-terminal region of βintegrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem. 2009; 284: 11485-97
|
|
|
|
|